|Bid||46.10 x 800|
|Ask||48.00 x 1000|
|Day's Range||47.07 - 47.47|
|52 Week Range||42.48 - 59.00|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||24.75|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.20|
HILDEN, Germany, & GERMANTOWN, Md., Jun 21, 2021--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.